Targeting p97-Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity

Nat Immunol. 2024 Sep;25(9):1623-1636. doi: 10.1038/s41590-024-01912-y. Epub 2024 Aug 6.

Abstract

Targeting tumor-infiltrating regulatory T (TI-Treg) cells is a potential strategy for cancer therapy. The ATPase p97 in complex with cofactors (such as Npl4) has been investigated as an antitumor drug target; however, it is unclear whether p97 has a function in immune cells or immunotherapy. Here we show that thonzonium bromide is an inhibitor of the interaction of p97 and Npl4 and that this p97-Npl4 complex has a critical function in TI-Treg cells. Thonzonium bromide boosts antitumor immunity without affecting peripheral Treg cell homeostasis. The p97-Npl4 complex bridges Stat3 with E3 ligases PDLIM2 and PDLIM5, thereby promoting Stat3 degradation and enabling TI-Treg cell development. Collectively, this work shows an important role for the p97-Npl4 complex in controlling Treg-TH17 cell balance in tumors and identifies possible targets for immunotherapy.

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Adenosine Triphosphatases / metabolism
  • Animals
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunotherapy / methods
  • LIM Domain Proteins / metabolism
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms / immunology
  • Nuclear Proteins / metabolism
  • STAT3 Transcription Factor / metabolism
  • T-Lymphocytes, Regulatory* / immunology
  • Th17 Cells / immunology

Substances

  • STAT3 Transcription Factor
  • Nuclear Proteins
  • LIM Domain Proteins
  • Adenosine Triphosphatases
  • Adaptor Proteins, Signal Transducing